Together, these studies show that pharmaceutical inhibition of BMP signaling together with the mitochondrial inhibitor Ym155 enhances AMPK activation and synergistically inhibits growth and induces cell death predominantly in LKB1 competent lung cancer cells. This evidence concerns the gene STK11 and lung cancer.